XML 49 R33.htm IDEA: XBRL DOCUMENT v3.25.4
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2025
Income Tax Disclosure [Abstract]  
Schedule of Domestic and Foreign Pre-Tax Loss
For the three years in the period ended December 31, 2025, domestic and foreign pre-tax loss were:
Year ended December 31,
202520242023
Loss before income taxes - Domestic$(453,630)$(297,441)$(208,829)
Loss before income taxes - Foreign(11,507)(497)(502)
Loss before income taxes - Consolidated$(465,137)$(297,938)$(209,331)
Schedule of Components of Income Tax Expense (Benefit)
The components of income tax expense are as follows in the period ended December 31, 2025:
Year ended December 31,
202520242023
Current expense:
U.S. Federal$— $— $— 
State— — — 
Foreign180 — — 
Total current expense (benefit)180 — — 
Deferred expense:— — — 
U.S. Federal— — — 
State— — — 
Foreign— — — 
Total deferred expense (benefit)— — — 
Total expense (benefit)$180 $— $— 
Schedule of Reconciliation of Income Tax Expense
A reconciliation of income tax expense to the amount computed by applying the statutory federal income tax rate to the loss from operations for the three years in the period ended December 31, 2025 is as follows:
Year ended December 31,
202520242023
Tax computed at federal statutory rate$(97,679)21.00 %$(62,666)21.00 %$(45,051)21.00 %
State tax, net of federal income tax effect (1)(884)0.19 %(593)0.20 %(375)0.17 %
Foreign tax effects2,595 (0.56)%104(0.03)%105(0.05)%
Non-taxable or nondeductible items
Stock-based compensation104 (0.02)%(7,395)2.47 %1,252 (0.58)%
Other4,208 (0.90)%2,487 (0.84)%167 (0.08)%
Changes in valuation allowance108,651 (23.36)%84,071 (28.17)%56,780 (26.47)%
Tax credits
Federal R&D credits (2)(20,550)4.42 %(19,527)6.54 %(15,455)7.20 %
Other tax credits(240)0.05 %— — %— — %
Changes in unrecognized tax benefits3,966 (0.85)%3,515 (1.18)%2,691 (1.25)%
Other adjustments
Other(0.01)%0.01 %(114)0.06 %
Provision for income taxes$180 (0.04)%$— — %$— — %
(1) The states that contribute to the majority (greater than 50%) of the tax effect in this category include California for 2025, 2024, and 2023.
(2) Federal R&D credits include research and development and orphan drug credits.
Schedule of Income Taxes Paid, Net of Refunds
A summary of income taxes paid, net of refunds received, for the year ended December 31, 2025, 2024, and 2023 are as follows:
Year ended December 31,
202520242023
Foreign
Australia89 — — 
Income taxes paid, net$89 $— $— 
Schedule of Deferred Tax Assets and Liabilities
Net deferred tax assets are comprised of the following as of December 31, 2025 and 2024:
December 31,
20252024
Deferred tax assets:
Net operating loss carryforwards$201,110 $109,135 
Capitalized research expenses71,799 83,785 
R&D and other tax credits79,999 57,901 
Stock-based compensation23,420 18,090 
Lease liabilities10,490 11,592 
Accrued expenses and other, net11,035 7,488 
Equity method investment3,418 3,544 
Total deferred tax assets401,271 291,535 
Less: valuation allowance(392,031)(281,784)
Total deferred tax assets after valuation allowance9,240 9,751 
Deferred tax liabilities:
Right-of use assets(8,750)(9,751)
Other deferred tax liabilities(490)— 
Total deferred tax liabilities(9,240)(9,751)
Net deferred tax assets$— $— 
Schedule of Unrecognized Tax Benefits
A summary of the Company's total unrecognized stock-based compensation expense, as of December 31, 2025, is as follows:
Unrecognized Stock-Based
Compensation Expense
(in thousands)
Average Remaining
Vesting Period
(in years)
Stock option awards$122,413 2.4
RSU awards$61,297 2.7
ESPP$6,600 1.4
Changes to the Company’s unrecognized tax benefits are summarized in the following table:
Year ended December 31,
202520242023
Beginning balance$10,689 $6,946 $4,110 
Increase (decrease) for prior year tax positions(20)(85)188 
Increase (decrease) for current year tax positions4,083 3,828 2,648 
Decreases due to settlements— — — 
Expiration of the statute of limitations for the assessment of taxes— — — 
Ending balance$14,752 $10,689 $6,946